A foundation built on Professionalism, Honesty and Decisiveness
Pharmadax uses its unique formulation technology platform specializing in development of modified release oral solid formulations. Quality and compliance is our core ideology, which is expressed in our products, people and partnerships.
Pharmadax is committed to develop modified release generics in various therapeutic segments with our oral solid controlled-release and oral pellet controlled-release systems. The team brings a good mix of innovation and timely execution to ensure efficient dossier filing.
We have a technology platform of high precision modified release, which can be used on large gamut molecules.
Our scientists ensure that this cutting edge technology continues to be flexible to bring more bioequivalent products to market.
Pharmadax was founded by two Pharma Technocrats, with a core idea of bringing quality pharmaceuticals with efficient technological advantage to the market at a justifiable price. Thus creating a value proposition for each stakeholder. Having successfully founded two companies together, this partnership came naturally.
Won the 12th Annual Golden Torch Awards of Enterprise Excellence of R.O.C.
Mr. Yipin Huang
- 25+ years of experience in pharmaceutical industry
- St. John’s University MSc in Industrial Pharmacy
- Was Anchen Inc.(US)-Director of the Board & Senior VP
- Was Anchen Inc. Taiwan Branch-Director of the Board & President
- Empax Pharma Inc.-Founder& Director of the Board& President
Ms. Huiju Chan
- 28+ years of experience in pharmaceutical industry
- Soochow University EMBA management
- Was Anchen Inc. Taiwan Branch-Director of the Board& Vice President
- Empax Pharma Inc-Founder& Director of the Board& Vice President
Our experienced team has average 15+ years of experince in develpoing and commercialising complex genenrics. We have major focus on CNS and CVS Segment. We ensure that we do not compromise on our core ideology of PHD (Professionalism, Honesty and Decisiveness)
Our Therapeutic focus is majorly on CNS and CVS areas, although we have library of proof of concepts across therapeutic areas.
SIHUAN PHARMACEUTICAL INVESTS IN PHARMADAX (FOSHAN) CO., LTD.
Wednesday, 6 Sep 2017
Hainan Sihuan Pharmaceutical, a wholly-owned subsidiary of the SIHUAN Pharmaceutical, recently entered into agreements (the “Agreements”) with, among others, PharmaDax Inc. (“PharmaDax”). According to the Agreements, the Group will invest in PharmaDax (FoShan) Co., Ltd ( “PharmaDax Foshan”), a subsidiary of the PharmaDax, in phases.
No token or token has expired.